Gilead Sciences Inc. (NASDAQ:GILD) Director John W. Madigan sold 105,000 shares of the company’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares in the company, valued at $9,115,028.46. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) opened at 75.30 on Thursday. Gilead Sciences Inc. has a 12-month low of $71.39 and a 12-month high of $108.63. The firm has a market cap of $99.20 billion, a PE ratio of 6.96 and a beta of 1.25. The firm’s 50-day moving average is $74.67 and its 200-day moving average is $80.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the consensus estimate of $2.87 by $0.12. The business earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The firm’s quarterly revenue was down 9.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.22 EPS. Equities analysts expect that Gilead Sciences Inc. will post $11.47 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.

GILD has been the topic of several recent research reports. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Monday, October 3rd. Jefferies Group decreased their target price on shares of Gilead Sciences from $93.00 to $91.00 and set a “hold” rating for the company in a research note on Wednesday, August 31st. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $108.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, September 22nd. Ten analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $97.90.

A number of hedge funds have recently bought and sold shares of GILD. Van Hulzen Asset Management LLC boosted its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 774 shares during the period. Gemmer Asset Management LLC boosted its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the period. Joel Isaacson & Co. LLC boosted its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Finally, Roble Belko & Company Inc boosted its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the period. Institutional investors own 76.65% of the company’s stock.

WARNING: This piece of content was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/john-w-madigan-sells-105000-shares-of-gilead-sciences-inc-gild-stock.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.